Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.58 |
| ▸ | PPARA | Q07869 | 16/20 | 0.58 |
| ▸ | PPARD | Q03181 | 12/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.34 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765972 | 0.92 | PPARA (0.69) | PPARGPPARAPPARDMAPTSMN1; SMN2 | |
| SCHEMBL30003432 | 0.88 | PPARG (0.56) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL24658609 | 0.88 | PPARG (0.56) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL1765978 | 0.84 | PPARA (0.61) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL376949 | 0.84 | PPARG (0.51) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL376765 | 0.83 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL377168 | 0.83 | PPARA (0.52) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL13296176 | 0.83 | PPARG (0.52) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL1765866 | 0.83 | PPARA (0.45) | PPARGPPARAPPARDHSD17B10NPC1 | |
| SCHEMBL377020 | 0.83 | PPARA (0.66) | PPARGPPARAPPARDHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310494-B1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-6787552-B2 | HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040097739-A1 | Ppar delta activators | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1310494-A1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097739-A1 | Ppar delta activators | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.